Autolus Therapeutics plc (AUTL)
NASDAQ: AUTL · Real-Time Price · USD
1.480
+0.060 (4.23%)
At close: Apr 28, 2026, 4:00 PM EDT
1.490
+0.010 (0.68%)
After-hours: Apr 28, 2026, 7:55 PM EDT
Autolus Therapeutics Employees
As of December 31, 2025, Autolus Therapeutics had 754 total employees, including 752 full-time and 2 part-time employees. The number of employees increased by 104 or 16.00% compared to the previous year.
Employees
754
Change (1Y)
104
Growth (1Y)
16.00%
Revenue / Employee
$99,984
Profits / Employee
-$381,337
Market Cap
393.89M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Vanda Pharmaceuticals | 533 |
| Rocket Pharmaceuticals | 202 |
| Puma Biotechnology | 179 |
| Invivyd | 122 |
| Enanta Pharmaceuticals | 120 |
| Niagen Bioscience | 117 |
| Neumora Therapeutics | 96 |
| Century Therapeutics | 78 |
AUTL News
- 7 days ago - Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 21 days ago - Autolus Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 4 weeks ago - Autolus Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates - GlobeNewsWire
- 6 weeks ago - Autolus Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 27, 2026 - GlobeNewsWire
- 3 months ago - Autolus Therapeutics Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Net Product Revenue, Pipeline Advancements and Outlook for 2026 - GlobeNewsWire
- 4 months ago - Autolus Therapeutics to Evaluate Automated Manufacturing of AUCATZYL® (obe-cel) on the Cellares Cell Shuttle™ Platform - GlobeNewsWire
- 4 months ago - Autolus Therapeutics to Evaluate Automated Manufacturing of AUCATZYL® (obe-cel) on the Cellares Cell ShuttleTM Platform - Business Wire
- 5 months ago - Autolus Therapeutics Presents Updated Clinical Data from the CARLYSLE Trial in Patients with Severe Refractory Systemic Lupus Erythematosus at the American Society of Hematology (ASH) Annual Meeting 2025 - GlobeNewsWire